These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296 [TBL] [Abstract][Full Text] [Related]
13. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM; J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692 [TBL] [Abstract][Full Text] [Related]
14. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Zeitler K; Salvas B; Stevens V; Brown J Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356 [TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781 [TBL] [Abstract][Full Text] [Related]
17. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF). Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195 [TBL] [Abstract][Full Text] [Related]